This is a phase 2 study that evaluates Lorundrostat in adults with Hypertension, Chronic Kidney Disease, and Albuminuria.
MLS-101-206
A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA
Chronic kidney disease
All genders
18-100
Recruiting now
Overview
Principal Investigator: Lesley Inker
Contact Us
Maz Ahmad
Study details
Inclusion Criteria
- UARC within 300-3500 mg/g in First morning void.
- At Screening, AOBP SBP of 135-180 mmHg, inclusive
- On a stable treatment with an ACEi or ARB for at least 2 months prior to Screening
Exclusion Criteria
- Subjects with known hypersensitivity to lorundrostat or any of its respective excipients
- Treatment, or anticipated treatment, with triamterene and amiloride
- Serum potassium >5.0 mmol/L at the Screening Visit and >4.8 mmol/L at Week 0 visit (prior to first dosing of study drug)
Study Requirements
10 visits in part A of assessments over the course of 26 weeks and 7 visits in part B of assessments of the course of 14 weeks. Blood draws would regularly occure.